Total Payments
$759,685
2024 Payments
$36,765
Companies
20
Transactions
254
Medicare Patients
20,249
Medicare Billing
$2.5M
Payment Breakdown by Category
Research$598,538 (78.8%)
Consulting$125,729 (16.6%)
Other$25,385 (3.3%)
Food & Beverage$5,829 (0.8%)
Travel$4,152 (0.5%)
Education$52.84 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $598,538 | 68 | 78.8% |
| Consulting Fee | $125,729 | 26 | 16.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,385 | 12 | 3.3% |
| Food and Beverage | $5,829 | 129 | 0.8% |
| Travel and Lodging | $4,152 | 14 | 0.5% |
| Education | $52.84 | 5 | 0.0% |
Payments by Type
Research
$598,538
68 transactions
General
$161,148
186 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $437,892 | 29 | $0 (2024) |
| Allergan, Inc. | $264,661 | 133 | $0 (2022) |
| Galderma Laboratories, L.P. | $40,045 | 53 | $0 (2024) |
| Almirall LLC | $6,149 | 5 | $0 (2019) |
| DERMIRA, INC. | $5,622 | 5 | $0 (2019) |
| Merz North America, Inc. | $4,681 | 6 | $0 (2022) |
| REVANCE THERAPEUTICS, INC. | $163.50 | 4 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $77.03 | 3 | $0 (2020) |
| Horizon Therapeutics plc | $63.43 | 1 | $0 (2023) |
| Bioventus LLC | $59.48 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,765 | 15 | ABBVIE INC. ($36,493) |
| 2023 | $389,745 | 26 | AbbVie Inc. ($389,208) |
| 2022 | $28,854 | 34 | Galderma Laboratories, L.P. ($16,230) |
| 2021 | $13,074 | 22 | Allergan, Inc. ($13,009) |
| 2020 | $123,614 | 35 | Allergan, Inc. ($113,156) |
| 2019 | $109,655 | 56 | Allergan Inc. ($101,596) |
| 2018 | $22,985 | 29 | Allergan Inc. ($12,640) |
| 2017 | $34,994 | 37 | Allergan Inc. ($23,920) |
All Payment Transactions
254 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $4.90 | General |
| 09/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Oncology | ||||||
| 08/23/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $110.94 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 07/10/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $31.21 | General |
| 05/29/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $15.01 | General |
| 04/15/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $36,000.00 | General |
| 04/01/2024 | Smith+Nephew, Inc. | COLLAGENASE SANTYL (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Pharma Products | ||||||
| 03/09/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $29.86 | General |
| 03/04/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 03/01/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 02/27/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $13.45 | General |
| 02/24/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $130.00 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 02/23/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $326.43 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 11/04/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $16.03 | General |
| 09/21/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $63.43 | General |
| Category: TEPEZZA | ||||||
| 09/14/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $795.00 | Research |
| Study: A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence • Category: FACIAL AESTHETICS | ||||||
| 08/14/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $2,322.50 | Research |
| Study: A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence • Category: FACIAL AESTHETICS | ||||||
| 08/04/2023 | Galderma Laboratories, L.P. | DYSPORT (Biological) | Food and Beverage | In-kind items and services | $129.69 | General |
| 08/04/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $58.09 | General |
| 07/13/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $4,582.50 | Research |
| Study: A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence • Category: FACIAL AESTHETICS | ||||||
| 06/21/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 06/15/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $6,275.00 | Research |
| Study: A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines • Category: FACIAL AESTHETICS | ||||||
| 06/15/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $2,930.00 | Research |
| Study: A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence • Category: FACIAL AESTHETICS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | AbbVie Inc. | $334,006 | 4 |
| Ph 3 Pivotal GL Only - US/EU | Allergan, Inc. | $68,546 | 18 |
| A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | AbbVie Inc. | $47,215 | 8 |
| A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition | Allergan, Inc. | $41,540 | 14 |
| Ph 3 Pivotal GL Only - USEU | Allergan Inc. | $40,803 | 6 |
| A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition | Allergan Inc. | $26,338 | 6 |
| A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVEDERM VOLUXA XC injectable gel for restoring jawline definition | Allergan Inc. | $9,772 | 1 |
| A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVEDERM VOLUX XC injectable gel for restoring jawline definition | Allergan, Inc. | $9,350 | 1 |
| A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVEDERM VOLUMA XC injectable gel for restoring jawline definition | Allergan Inc. | $6,357 | 1 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | AbbVie Inc. | $6,000 | 1 |
| Ph 3 Open-label Extension Study | Allergan, Inc. | $5,000 | 1 |
| A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | AbbVie Inc. | $1,966 | 2 |
| A MULTICENTER, EVALUATOR-BLINDED, RANDOMIZED, PARALLEL-GROUP, CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF JUVEDERM VOLUMA XC INJECTABLE GEL FOR CORRECTION OF TEMPLE HOLLOWING | Allergan, Inc. | $1,188 | 3 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $456.43 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 3,483 | 6,246 | $731,594 | $442,013 |
| 2022 | 25 | 3,808 | 7,251 | $756,398 | $470,173 |
| 2021 | 30 | 5,851 | 10,950 | $1.1M | $702,485 |
| 2020 | 36 | 7,107 | 13,034 | $1.3M | $866,413 |
Total Patients
20,249
Total Services
37,481
Medicare Billing
$2.5M
Procedure Codes
115
All Medicare Procedures & Services
115 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 189 | 224 | $149,875 | $105,198 | 70.2% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 130 | 204 | $82,516 | $61,665 | 74.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 730 | 937 | $83,888 | $48,199 | 57.5% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 138 | 162 | $68,375 | $37,608 | 55.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 706 | 916 | $60,589 | $34,022 | 56.2% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 119 | 136 | $63,795 | $27,373 | 42.9% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 51 | 56 | $35,123 | $25,063 | 71.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 220 | 241 | $23,948 | $14,428 | 60.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 208 | 208 | $23,304 | $13,425 | 57.6% |
| 17314 | Removal and microscopic exam of growth of trunk, arms, or legs, each additional stage, 1-5 tissue blocks | Office | 2023 | 31 | 43 | $16,586 | $12,424 | 74.9% |
| 13101 | Complicated repair of wound of trunk, 2.6-7.5 cm | Office | 2023 | 46 | 49 | $19,278 | $12,124 | 62.9% |
| 13152 | Complicated repair of wound of eyelids, nose, ears, or lip, 2.6-7.5 cm | Office | 2023 | 53 | 55 | $27,276 | $11,113 | 40.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 520 | 2,606 | $16,765 | $10,874 | 64.9% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 46 | 48 | $13,338 | $4,977 | 37.3% |
| 17315 | Removal and microscopic exam of growth, each additional block after 5 tissue blocks | Office | 2023 | 35 | 82 | $6,411 | $4,805 | 75.0% |
| 11604 | Removal of cancer skin growth of body, arms, or legs, 3.1-4.0 cm | Office | 2023 | 32 | 33 | $10,182 | $3,817 | 37.5% |
| 13122 | Complicated repair of wound of scalp, arms, or legs, each additional 5.0 cm or less | Office | 2023 | 28 | 28 | $3,590 | $2,678 | 74.6% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 25 | 28 | $6,797 | $2,531 | 37.2% |
| 13151 | Complicated repair of wound of eyelids, nose, ears, or lip, 1.1-2.5 cm | Office | 2023 | 14 | 15 | $6,335 | $2,367 | 37.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 36 | $4,521 | $1,873 | 41.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 42 | 52 | $2,574 | $1,774 | 68.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 50 | 51 | $2,843 | $1,584 | 55.7% |
| 69100 | Biopsy of ear | Office | 2023 | 22 | 23 | $2,197 | $1,076 | 49.0% |
| 10040 | Acne surgery | Office | 2023 | 13 | 13 | $1,489 | $1,015 | 68.2% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 176 | 203 | $135,821 | $97,111 | 71.5% |
About Dr. Susan Weinkle, M.D
Dr. Susan Weinkle, M.D is a Specialist healthcare provider based in Bradenton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992897938.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Weinkle, M.D has received a total of $759,685 in payments from pharmaceutical and medical device companies, with $36,765 received in 2024. These payments were reported across 254 transactions from 20 companies. The most common payment nature is "" ($598,538).
As a Medicare-enrolled provider, Weinkle has provided services to 20,249 Medicare beneficiaries, totaling 37,481 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 115 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Bradenton, FL
- Active Since 09/28/2006
- Last Updated 07/22/2008
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992897938
Products in Payments
- BOTOX (Biological) $404,403
- QBREXZA (Drug) $5,622
- XEOMIN (Biological) $4,471
- BOTOX COSMETIC (Biological) $208.21
- SOOLANTRA (Drug) $189.69
- Xeomin (Biological) $184.67
- DAXXIFY (Drug) $163.50
- DYSPORT (Biological) $129.69
- ALTRENO (Drug) $77.03
- TEPEZZA (Drug) $63.43
- SPEVIGO (Drug) $46.63
- AMELUZ (Drug) $46.40
- BLU-U (Medical Supply) $37.66
- ENSTILAR (Drug) $23.71
- Puraply Antimicrobial (Medical Supply) $22.02
- LIBTAYO (Biological) $20.30
- ESKATA (Drug) $18.36
- Odomzo (Drug) $16.26
- Otezla (Drug) $15.75
- COLLAGENASE SANTYL (Drug) $13.88
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Bradenton
Moonasar Rampertaap, Md, MD
Specialist — Payments: $238,026
Specialist $238,026
Dr. Eva Laukhuf, M.d, M.D
Specialist — Payments: $5,852
Specialist $5,852
Dr. Christopher Davis, M.d, M.D
Specialist — Payments: $4,647
Specialist $4,647
Dr. Constance Charles-Logan, M.d, M.D
Specialist — Payments: $2,029
Specialist $2,029
Dr. Terrence Hopkins, M. D, M. D
Specialist — Payments: $1,657
Specialist $1,657
Dr. Dalibor Hradek, M.d, M.D
Specialist — Payments: $954.58
Specialist $954.58